Document is current
Any future updates will be listed below
-
Authors
Rockowitz, Shira https://orcid.org/0000-0003-1490-592X
LeCompte, Nicholas https://orcid.org/0000-0002-2330-7772
Carmack, Mary https://orcid.org/0000-0003-4546-790X
Quitadamo, Andrew https://orcid.org/0000-0001-8748-4586
Wang, Lily
Park, Meredith
Knight, Devon https://orcid.org/0000-0002-7116-8690
Sexton, Emma https://orcid.org/0000-0003-4776-5230
Smith, Lacey https://orcid.org/0000-0002-4456-0072
Sheidley, Beth
Field, Michael https://orcid.org/0000-0002-4003-0568
Holm, Ingrid A. https://orcid.org/0000-0003-4712-8821
Brownstein, Catherine A.
Agrawal, Pankaj B.
Kornetsky, Susan
Poduri, Annapurna https://orcid.org/0000-0002-7350-5136
Snapper, Scott B.
Beggs, Alan H. https://orcid.org/0000-0001-8818-0568
Yu, Timothy W.
Williams, David A.
Sliz, Piotr https://orcid.org/0000-0002-6522-0835
- License Information
-
More Information
Article History
Received: 23 November 2019
Accepted: 3 June 2020
First Online: 6 July 2020
Competing interests
: S.B.S. participates on the scientific advisory board for Pfizer, Takeda, Janssen, Celgene, Lilly, IFM therapeutics, and Pandion Inc. and consulted for Hoffman La Roche and Amgen. He currently has grant support from Pfizer and Novartis, and in-kind support for sequencing from Regeneron. He has previously received grant funding from Janssen and Merck and in-kind support for sequencing from Merck. T.W.Y. participates on the scientific advisory board of GeneTx Biotherapeutics and Eisai, Inc., and has consulted for Alnylam Pharmaceuticals. The remaining authors declare no competing interests.
